Literature DB >> 6988274

Decrease of antibodies to insulin, proinsulin and contaminating hormones after changing treatment from conventional beef to purified pork insulin.

A B Kurtz, J A Matthews, B E Mustaffa, P R Daggett, J D Nabarro.   

Abstract

The sera of 30 patients who had been treated with conventional beef insulin were tested for binding of insulin and other pancreatic hormones. All showed antibody binding of insulin, 29 binding of proinsulin, 29 binding of pancreatic polypeptide, two binding of glucagon but none of the sera bound vasoactive intestinal peptide or somatostatin. After changing therapy to highly purified pork insulin the binding capacity of sera for insulin and the other hormones was monitored for up to 35 months and a steady fall was found in nearly all cases. In eight of the patients conventional beef insulin treatment was resumed: in one month binding of insulin and of the other hormones increased back to the initial levels. In eighteen subjects who had only received highly purified pork insulin low levels of insulin binding were found with no binding of proinsulin or other hormones. The amounts of proinsulin and contaminating hormones in highly purified pork insulin are so low that they are not immunogenic; conventional beef insulin not only contains immunogenic amounts of proinsulin and the contaminating hormones pancreatic polypeptide and glucagon but also is more immunogenic than purified pork insulin.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6988274     DOI: 10.1007/BF00290492

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  15 in total

1.  An enzymatic solid-phase method for trace iodination of proteins and peptides with 125-iodine.

Authors:  S L Karonen; P Mörsky; M Siren; U Seuderling
Journal:  Anal Biochem       Date:  1975-07       Impact factor: 3.365

2.  The prevalence of proinsulin-specific antibodies in diabetic patients.

Authors:  D Kumar; L V Miller
Journal:  Horm Metab Res       Date:  1973-01       Impact factor: 2.936

3.  Clinical aspects of insulin--antigenicity.

Authors:  J Schlichtkrull; J Brange; A H Christiansen; O Hallund; L G Heding; K H Jorgensen
Journal:  Diabetes       Date:  1972       Impact factor: 9.461

4.  Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays.

Authors:  B Desbuquois; G D Aurbach
Journal:  J Clin Endocrinol Metab       Date:  1971-11       Impact factor: 5.958

5.  Letter: Highly purified insulins.

Authors:  J G Devlin; V Parameswaran
Journal:  Lancet       Date:  1976-06-19       Impact factor: 79.321

6.  Human serum proinsulin.

Authors:  F Melani; A H Rubenstein; D F Steiner
Journal:  J Clin Invest       Date:  1970-03       Impact factor: 14.808

7.  Effect of "fractionated" insulins on total plasma insulin binding capacity and insulin requirements in severe diabetes.

Authors:  N W Oakley
Journal:  Lancet       Date:  1976-05-08       Impact factor: 79.321

8.  Autoimmunity in diabetics induced by hormonal contaminants of insulin.

Authors:  S R Bloom; T E Adrian; A J Barnes; J M Polak
Journal:  Lancet       Date:  1979-01-06       Impact factor: 79.321

9.  Insulin binding capacity in patients changed from conventional to highly purified insulins. An indicator of likely response.

Authors:  B E Mustaffa; P R Daggett; J D Nabarro
Journal:  Diabetologia       Date:  1977-08       Impact factor: 10.122

10.  Proinsulin and A-component antibodies in diabetics after long-term monocomponent insulin treatment.

Authors:  B Bruni; S Gamba; G Regis; G L Turco
Journal:  Diabetologia       Date:  1978-03       Impact factor: 10.122

View more
  20 in total

1.  Prevalence of islet cell antibodies, insulin antibodies and hyperglycaemia in 2291 schoolchildren.

Authors:  M Bergua; J Solé; G Marion; M C Perez; A Recasens; J Fernàndez; R Casamitjana; R Gomis
Journal:  Diabetologia       Date:  1987-09       Impact factor: 10.122

2.  Antibody responses following change-over to mixed species (porcine/bovine) insulins.

Authors:  M I Drury; D Cregan; R M Drury; A B Kurtz; S R Bloom; L S Gerlis
Journal:  Ir J Med Sci       Date:  1983-09       Impact factor: 1.568

Review 3.  Insulin antibody determination: theoretical and practical considerations.

Authors:  W G Reeves
Journal:  Diabetologia       Date:  1983-06       Impact factor: 10.122

Review 4.  Circulating insulin-binding antibodies.

Authors:  A B Kurtz; J D Nabarro
Journal:  Diabetologia       Date:  1980-10       Impact factor: 10.122

5.  Effect of cyclosporin A treatment on the production of antibody in insulin-dependent (type I) diabetic patients.

Authors:  C Boitard; G Feutren; L Castano; M Debray-Sachs; R Assan; J Hors; J F Bach
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

6.  HLA antigens and other risk factors in the development of retinopathy in type 1 diabetes.

Authors:  R S Gray; I R Starkey; S Rainbow; A B Kurtz; A Abdel-Khalik; S Urbaniak; R A Elton; L J Duncan; B F Clarke
Journal:  Br J Ophthalmol       Date:  1982-05       Impact factor: 4.638

7.  The human cellular immune response to insulin: a study in unexposed control subjects and type I diabetic patients on acute and chronic treatment.

Authors:  E R Richens; M E Seward; W A Luqman; M Hartog
Journal:  Acta Diabetol Lat       Date:  1986 Oct-Dec

8.  An investigation into cytotoxic mechanisms in type I diabetes mellitus.

Authors:  E R Richens; J Quilley; M Hartog
Journal:  Acta Diabetol Lat       Date:  1982 Oct-Dec

9.  Immunogenicity of highly purified bovine insulin: a comparison with conventional bovine and highly purified human insulins.

Authors:  R M Wilson; C A Douglas; R B Tattersall; W G Reeves
Journal:  Diabetologia       Date:  1985-09       Impact factor: 10.122

10.  The determination of detection limits for insulin antibody assays.

Authors:  A B Kurtz; L DiSilvio; E Bosi
Journal:  Diabetologia       Date:  1988-06       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.